ARAY Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -1.15% compared to Accuray's net margin of 14.45%. Accuray's return on equity of 1.47% beat Boston Scientific's return on equity of 9.57%.

Accuray has a consensus price target of $5.17, signalling upside risk potential of 279.9%. On the other hand Boston Scientific has an analysts' consensus of $117.45 which suggests that it could grow by 13.81%. Given that Accuray has higher upside potential than Boston Scientific, analysts believe Accuray is more attractive than Boston Scientific.

Accuray has a beta of 1.260, which suggesting that the stock is 25.978% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Accuray's net income of -$1.3M is lower than Boston Scientific's net income of $674M. Notably, Accuray's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 75.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.30x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -1.15% compared to Accuray's net margin of --. Accuray's return on equity of 1.47% beat Perspective Therapeutics's return on equity of --.

Accuray has a consensus price target of $5.17, signalling upside risk potential of 279.9%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 254.45%. Given that Accuray has higher upside potential than Perspective Therapeutics, analysts believe Accuray is more attractive than Perspective Therapeutics.

Accuray has a beta of 1.260, which suggesting that the stock is 25.978% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Accuray's net income of -$1.3M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Accuray's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.30x versus 28.05x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -1.15% compared to Accuray's net margin of -5.14%. Accuray's return on equity of 1.47% beat Integer Holdings's return on equity of 4.85%.

Accuray has a consensus price target of $5.17, signalling upside risk potential of 279.9%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 24%. Given that Accuray has higher upside potential than Integer Holdings, analysts believe Accuray is more attractive than Integer Holdings.

Accuray has a beta of 1.260, which suggesting that the stock is 25.978% more volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are smaller than Integer Holdings quarterly revenues of $437.4M. Accuray's net income of -$1.3M is higher than Integer Holdings's net income of -$22.5M. Notably, Accuray's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 56.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.30x versus 2.42x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -1.15% compared to Accuray's net margin of 0.18%. Accuray's return on equity of 1.47% beat Xtant Medical Holdings's return on equity of -26.62%.

Accuray has a consensus price target of $5.17, signalling upside risk potential of 279.9%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 167.18%. Given that Accuray has higher upside potential than Xtant Medical Holdings, analysts believe Accuray is more attractive than Xtant Medical Holdings.

Accuray has a beta of 1.260, which suggesting that the stock is 25.978% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Accuray quarterly revenues are $113.2M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Accuray's net income of -$1.3M is lower than Xtant Medical Holdings's net income of $58K. Notably, Accuray's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.30x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.